Skip to main content
. 2023 May 23;13(9):3583–3597. doi: 10.1016/j.apsb.2023.05.023

Figure 1.

Figure 1

Preferred targets and combinations. (A) The top 10 most widely investigated targets. (B) The top 10 most widely investigated targets–clinical stage. (C) Top 10 selected target combinations of cell-bridging bsAbs and (D) their clinical phases. (E) Top 10 selected target combinations of non-cell-bridging bsAbs and (F) their clinical phases. Information was obtained from Cortellis Drug Discovery Intelligence (https://www.cortellis.com/drugdiscovery/home)12.